AboutThe recipient of multiple international design awards, Atomo creates devices that address the problems commonly associated with standard multi-component rapid diagnostic test kits
Our ProductsThe unique design and built-in features of Atomo products make them simpler to use than standard multi-component test kits, with less scope for user errors.
Why Atomo?Our track record in reimagining point of care diagnostics and expertise in device development mean we can offer you best-in-class OEM solutions with excellent usability, convenience, and performance.
An article from political journalist Tom McIlroy in The Financial Review regarding the way in which the approach towards self testing of COVID-19 has revolutionised the way in which the HIV self testing market operates.
Co-founder and Managing Director, John Kelly, chats with Phil Muscatello on The Equity ASA podcast, produced for the Australian Shareholders’ Association.
Atomo Diagnostics (ASX:AT1) and Viatris to Support HIV Self-Test Supply
April 29, 2021
An article by Carolyn Rebeiro in The Market Herald on our support for Unitaid’s quest to expand access to HIV self-test supply to low- and middle-income countries.
Our MD, John Kelly sat down with Ausbiz to discuss our rapid antigen test deal with Access Bio which will enable screening for acute infection and exposure at the same time.
Why the Atomo (ASX:AT1) share price is moving higher today
September 29, 2020
An article by Aaron Teboneras of the Motley Fool on our expanded a partnership with Access Bio to launch a rapid antigen test in Australia, New Zealand and India.
